Analysis of large publicly available CRC datasets30,31 revealed that of the 17 BRAF-controlled WNT antagonist genes only DKK1, CDH1, SOSTDC1, and FAM3D were consistently expressed to significantly lower levels in BRAF-mutant CRCs versus BRAF-wildtype CRCs (Figures 3C–3F, S11, and S12). This evidence concerns the gene DKK1 and colorectal carcinoma.